Compare STRO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | ABOS |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.4M | 147.5M |
| IPO Year | 2018 | 2021 |
| Metric | STRO | ABOS |
|---|---|---|
| Price | $8.89 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $47.23 | $7.60 |
| AVG Volume (30 Days) | 279.9K | ★ 574.6K |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,419,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $1.50 |
| 52 Week High | $43.85 | $3.60 |
| Indicator | STRO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 21.28 | 58.01 |
| Support Level | N/A | $2.13 |
| Resistance Level | $16.99 | $2.44 |
| Average True Range (ATR) | 1.24 | 0.16 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 7.84 | 96.75 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.